112197-88-3

Upstream product

• 1008779-94-9 methyl 3-hydroxypiperidine-3-carboxylate 
• 100-39-0 benzyl bromide 
• 1219832-34-4 tert-butyl 3-cyano-3-hydroxypiperidine-1-carboxylate 
• 98977-36-7 3-oxo-piperidine-1-carboxylic acid tert-butyl ester 
• 112197-76-9 1-benzyl-3-((trimethylsilyl)oxy)piperidine-3-carbonitrile 
• 40114-49-6 1-benzyl-3-piperidone 
• 67-56-1 methanol 
• 150018-99-8 1-benzyl-3-hydroxypiperidine-3-carbonitrile 

Downstream Products

• 112197-89-4 3-hydroxy-3-(hydroxymethyl)-1-(phenylmethyl)piperidine 
• 1008779-94-9 methyl 3-hydroxypiperidine-3-carboxylate 
• 923010-85-9 1'-tert-butyl 3-methyl 3-hydroxy-1,4'-bipiperidine-1',3-dicarboxylate 
• 923010-55-3 C₁₉H₃₁N₃O₅ 
• 923010-86-0 C₂₀H₃₃N₃O₅ 

Relevant academic research and scientific papers

CYCLIC AMIDES AS METAP-2 INHIBITORS

Compounds of the formula (I), in which R1, R3, R5, R6, R7, R, X and Y have the meanings indicated in Claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumou

Synthesis and Structure-Activity Studies of a Series of Spirooxazolidine-2,4-diones: 4-Oxa Analogues of the Muscarinic Agonist 2-Ethyl-8-methyl-2,8-diazaspirodecane-1,3-dione

A series of spirooxazolidine-2,4-dione derivatives related to the putative M1 agonist 2-ethyl-8-methyl-2,8-diazaspirodecane-1,3-dione (RS86; 1) were synthesized.The compounds were evaluated as cholinergic agents in in vitro binding assays and in in vivo pharmacological tests including antiamnesic effects using scopolamine-treated mice, hypothermia, and salivation in mice.Four compounds (5a,c,f and 17a) exhibited affinity for cortical M1 receptors and reversed scopolamine-induced impairment of mouse passive avoidance tasks, as did 1.Among these compounds only 5a exhibited M1-receptor stimulating activity in pithed rats.Structural requirements for muscarinic activity in this series of spirooxazolidine-2,4-dione derivatives were as strict as those reported for spirocuccinimide derivatives including 1.The antiamnesic dose of 3-ethyl-8-methyl-1-oxo-3,8-diazaspirodecane-2,4-dione (5a) was 2 orders of magnitude lower than the doses inducing hypothermia and salivation, in contrast to 1 for which the former dose was only 5-10-fold lower than the latter.These results suggest that the 8-azaspirodecane skeleton represents a useful template for designing new muscarinic agonists as antidementia drugs.

2-Methyl-1,3-dioxaazaspirodecanes as Novel Muscarinic Cholinergic Agonists

Many nonquaternary ammonium muscarinic agonists have been developed over the last few years, but most of the existing compounds (e.g., arecoline, RS-86, AF-30) behave as weak partial agonists at cholinergic receptors in tissues of limited receptor reserve